Search Results

Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.

https://www.cslseqirus.us/expertise/influenza

CSL Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.cslseqirus.us/expertise

CSL Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community.

https://www.cslseqirus.us/products

Data published in Molecular Therapy – Methods and Clinical Development confirm the potential preclinical benefit of the sa-mRNA technology platform, the next generation of mRNA vaccine technology

https://www.cslseqirus.us/news/csl-announces-positive-preclinical-data-for-self-amplifying-messenger-rna-flu-vaccine-candidates

CSL Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.cslseqirus.us/expertise/influenza/pandemic-response-solutions

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.cslseqirus.us/news

CSL Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.

https://www.cslseqirus.us/our-company

CSL Seqirus stands with our partners on the front line of public health. We are the largest fully integrated commercialisation partner in Australia and New Zealand. Learn more.

https://www.cslseqirus.us/partnering

This year marks the first full season that Seqirus’ portfolio of innovative influenza vaccines provides a differentiated vaccine option for people of all ages who are eligible in the U.S. to receive a flu shot

https://www.cslseqirus.us/news/seqirus-begins-shipping-portfolio-of-innovative-influenza-vaccines-for-the-2022-23-us-season

CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens

https://www.cslseqirus.us/news/csl-announces-closing-of-global-collaboration-and-licensing-agreement-with-arcturus-therapeutics